Previous 10 |
home / stock / avmxy / avmxy news
Avita Medical Ltd. ADR ( OTCQX:AVMXY ): Q2 Revenue of A$3.9M (+65.3% Y/Y) Press Release More news on: Avita Medical Ltd. ADR, Earnings news and commentary, Healthcare stocks news, ,
Recent Highlights Pre-launch U.S. product sales of A$1.1 million in second quarter Successful preparation for U.S. national market launch in January 2019 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at multiple bur...
RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that 26 abstracts highlighting the clinical and cost savings benefits...
News, Short Squeeze, Breakout and More Instantly...
Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, annou...
Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the he...
First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of...